Zylox Tonbridge Medical (2190 HK): No More Interventions Needed, Blockages Cleared for Growth
​Zylox-Tonbridge Medical carried forward 2024 momentum, moving into 1H25. New launches and strong market sales capabilities will help drive the...
342 Views
China Healthcare Weekly (Aug.31) - P/R Ratio Is Meaningless, Innovent, Zylox-Tonbridge 25H1 Results
The valuation method of "P/R" that is calculated by dividing market value by R&D expense is meaningless.Innovent turns profit, with valuation...
435 Views
Zylox-Tonbridge Medical Technology (2190.HK) - A Good Alpha-Generating Opportunity for Investors
​Zylox's strong fundamentals and growth potential have not been fully reflected in current valuation due to market conditions, making it a...
510 Views
Pre-IPO Zylox-Tonbridge Medical Technology - Promising Market with Challenges
This insights analyzed Zylox-Tonbridge Medical Technology in terms of the market potential, industry characteristics, business analysis, financial...
519 Views
China Healthcare Weekly (Aug.3)-Medical Device Valuation Repair,Deal on IBI363,WuXi AppTec Placement
​NHSA shifts focus from lowest price to quality in medical device VBP, indicating valuation repair.IBI363 license deal with MNC is expected. WuXi...
616 Views